CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aytu BioScience, Inc. - AYTU CFD

2.706
2.87%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.078
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Aytu Biopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.786
Open* 2.846
1-Year Change* 15.41%
Day's Range* 2.706 - 2.846
52 wk Range 1.38-3.65
Average Volume (10 days) 11.73K
Average Volume (3 months) 807.05K
Market Cap 13.70M
P/E Ratio -100.00K
Shares Outstanding 5.57M
Revenue 101.84M
EPS -6.17
Dividend (Yield %) N/A
Beta -1.23
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 2.786 -0.270 -8.84% 3.056 3.076 2.696
Apr 11, 2024 3.066 0.030 0.99% 3.036 3.136 3.026
Apr 10, 2024 3.126 -0.090 -2.80% 3.216 3.266 3.046
Apr 9, 2024 3.296 0.080 2.49% 3.216 3.316 3.216
Apr 8, 2024 3.266 0.360 12.39% 2.906 3.286 2.846
Apr 5, 2024 3.146 0.120 3.97% 3.026 3.196 3.026
Apr 4, 2024 3.136 0.230 7.91% 2.906 3.186 2.876
Apr 3, 2024 2.936 0.040 1.38% 2.896 3.106 2.896
Apr 2, 2024 2.966 0.080 2.77% 2.886 3.006 2.886
Apr 1, 2024 2.946 -0.010 -0.34% 2.956 3.096 2.916
Mar 28, 2024 3.006 0.050 1.69% 2.956 3.106 2.926
Mar 27, 2024 2.926 -0.040 -1.35% 2.966 3.016 2.846
Mar 26, 2024 2.966 -0.040 -1.33% 3.006 3.076 2.886
Mar 25, 2024 3.036 0.000 0.00% 3.036 3.106 3.036
Mar 22, 2024 2.876 -0.030 -1.03% 2.906 2.976 2.786
Mar 21, 2024 2.956 0.080 2.78% 2.876 2.986 2.826
Mar 20, 2024 2.846 0.110 4.02% 2.736 2.906 2.696
Mar 19, 2024 2.806 -0.050 -1.75% 2.856 2.876 2.756
Mar 18, 2024 2.816 0.110 4.07% 2.706 3.036 2.656
Mar 15, 2024 2.706 -0.120 -4.25% 2.826 2.856 2.706

Aytu BioScience, Inc. Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

20:00

Country

US

Event

Q3 2024 Aytu Biopharma Inc Earnings Release
Q3 2024 Aytu Biopharma Inc Earnings Release

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

16:00

Country

US

Event

Aytu Biopharma Inc Annual Shareholders Meeting
Aytu Biopharma Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, September 25, 2024

Time (UTC)

20:00

Country

US

Event

Q4 2024 Aytu Biopharma Inc Earnings Release
Q4 2024 Aytu Biopharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 107.399 96.669 65.632 27.6321 7.32036
Revenue 107.399 96.669 65.632 27.6321 7.32036
Cost of Revenue, Total 40.767 44.386 36.432 7.55303 2.20204
Gross Profit 66.632 52.283 29.2 20.0791 5.11832
Total Operating Expense 124.464 206.406 126.071 38.6481 33.9975
Selling/General/Admin. Expenses, Total 70.078 69.88 55.808 34.8024 19.2396
Research & Development 4.095 12.662 5.623 1.72142 0.58907
Depreciation / Amortization 4.788 5.844 6.009 4.49047 2.13626
Unusual Expense (Income) 5.705 75.289 22.199 -9.91925 9.83055
Operating Income -17.065 -109.737 -60.439 -11.016 -26.6772
Interest Income (Expense), Net Non-Operating 0.014 -0.757 -2.05 -2.60466 -0.45472
Net Income Before Taxes -17.051 -108.889 -58.03 -13.6207 -27.1319
Net Income After Taxes -17.051 -108.779 -58.289 -13.6207 -27.1319
Net Income Before Extra. Items -17.051 -108.779 -58.289 -13.6207 -27.1319
Net Income -17.051 -108.779 -58.289 -13.6207 -27.1319
Income Available to Common Excl. Extra. Items -17.051 -108.779 -58.289 -13.6207 -27.1319
Income Available to Common Incl. Extra. Items -17.051 -108.779 -58.289 -13.6207 -27.1319
Diluted Net Income -17.051 -108.779 -58.289 -13.6207 -27.1319
Diluted Weighted Average Shares 3.33991 1.46988 0.83733 0.22596 0.03897
Diluted EPS Excluding Extraordinary Items -5.10523 -74.0056 -69.6126 -60.2791 -696.182
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -3.3971 -40.7117 -52.3801 -104.177 -443.938
Total Extraordinary Items
Other, Net 1.605 4.459
Other Operating Expenses, Total -0.969 -1.655
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 30.732 22.733 26.279 27.655 27.448
Revenue 30.732 22.733 26.279 27.655 27.448
Cost of Revenue, Total 12.168 9.99 8.986 9.623 12.606
Gross Profit 18.564 12.743 17.293 18.032 14.842
Total Operating Expense 30.563 31.291 33.072 29.308 44.388
Selling/General/Admin. Expenses, Total 14.095 19.981 18.578 17.424 17.395
Research & Development 0.465 0.856 1.71 1.064 3.253
Depreciation / Amortization 1.195 1.198 1.198 1.197 1.298
Unusual Expense (Income) 3.105 0 2.6 10.809
Operating Income 0.169 -8.558 -6.793 -1.653 -16.94
Interest Income (Expense), Net Non-Operating -2.626 1.358 0.1 1.08 -0.761
Other, Net -0.128 1.612
Net Income Before Taxes -2.457 -7.2 -6.693 -0.701 -16.089
Net Income After Taxes -2.457 -7.2 -6.693 -0.701 -16.089
Net Income Before Extra. Items -2.457 -7.2 -6.693 -0.701 -16.089
Net Income -2.457 -7.2 -6.693 -0.701 -16.089
Income Available to Common Excl. Extra. Items -2.457 -7.2 -6.693 -0.701 -16.089
Income Available to Common Incl. Extra. Items -2.457 -7.2 -6.693 -0.701 -16.089
Diluted Net Income -2.457 -7.2 -6.693 -0.701 -16.089
Diluted Weighted Average Shares 4.06223 3.72678 3.1103 2.51791 2.73622
Diluted EPS Excluding Extraordinary Items -0.60484 -1.93196 -2.15188 -0.27841 -5.88
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS 0.15952 -1.93196 -1.31595 -0.27841 -1.92967
Other Operating Expenses, Total -0.465 -0.734 -0.973
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 72.832 59.929 105.234 75.4226 15.4329
Cash and Short Term Investments 22.985 19.36 49.649 48.0817 11.0442
Cash & Equivalents 22.985 19.36 49.649 48.0817 11.0442
Short Term Investments
Total Receivables, Net 28.937 21.712 28.176 5.63272 1.74079
Accounts Receivable - Trade, Net 28.937 21.712 28.176 5.63272 1.74079
Total Inventory 11.995 10.849 16.339 9.99944 1.44007
Prepaid Expenses 8.047 7.375 9.78 5.71509 0.95778
Total Assets 136.463 137.623 265.668 153.293 34.7214
Property/Plant/Equipment, Total - Net 3.869 6.296 8.703 0.89261 0.20373
Goodwill, Net 0 65.802 28.0904
Intangibles, Net 58.97 70.632 85.464 48.8546 19.0826
Other Long Term Assets, Total 0.792 0.766 0.465 0.03298 0.0022
Total Current Liabilities 69.015 64.442 109.438 28.7634 5.37258
Payable/Accrued 11.012 9.468 8.689 0.959
Accrued Expenses 37.045 35.946 49.485 11.1046 1.99724
Notes Payable/Short Term Debt 1.563 3.813 7.934 0 0
Other Current Liabilities, Total 5.832 4.132 7.407 4.87523 1.07807
Total Liabilities 97.106 91.531 128.1 58.2778 27.6336
Total Long Term Debt 14.713 14.279 0.18 0 0
Other Liabilities, Total 13.378 12.81 18.482 29.5145 22.261
Total Equity 39.357 46.092 137.568 95.0153 7.08782
Preferred Stock - Non Redeemable, Net 0 0 0 0 0.00036
Common Stock 0.001 0.004 0.003 0.00126 0.00175
Additional Paid-In Capital 343.485 334.56 315.864 215.024 113.475
Retained Earnings (Accumulated Deficit) -304.129 -288.472 -178.299 -120.01 -106.39
Total Liabilities & Shareholders’ Equity 136.463 137.623 265.668 153.293 34.7214
Total Common Shares Outstanding 5.51717 1.92894 1.37452 0.62919 0.08769
Other Current Assets, Total 0.868 0.633 1.29 5.9936 0.25
Accounts Payable 13.478 10.987 19.255 11.8246 2.29727
Property/Plant/Equipment, Total - Gross 7.55 8.717 9.715 1.37661 0.59973
Accumulated Depreciation, Total -3.681 -2.421 -1.012 -0.484 -0.396
Total Preferred Shares Outstanding 0 0 3.59498
Current Port. of LT Debt/Capital Leases 0.085 0.096 16.668 0
Capital Lease Obligations 0 0.084 0.18 0
Long Term Debt 14.713 14.195
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 70.599 72.832 78.465 70.611 74.415
Cash and Short Term Investments 19.964 22.985 19.179 19.501 23.811
Cash & Equivalents 19.964 22.985 19.179 19.501 23.811
Total Receivables, Net 29.882 28.937 34.043 25.547 27.924
Accounts Receivable - Trade, Net 29.882 28.937 34.043 25.547 27.924
Total Inventory 12.966 11.995 13.637 12.95 12.871
Prepaid Expenses 7.038 8.047 10.429 11.989 9.024
Other Current Assets, Total 0.749 0.868 1.177 0.624 0.785
Total Assets 132.888 136.463 147.216 141.436 150
Property/Plant/Equipment, Total - Net 4.176 3.869 4.395 5.019 5.648
Property/Plant/Equipment, Total - Gross 8.166 7.55 7.779 8.083 8.384
Accumulated Depreciation, Total -3.99 -3.681 -3.384 -3.064 -2.736
Goodwill, Net
Intangibles, Net 57.341 58.97 63.464 64.985 69.108
Other Long Term Assets, Total 0.772 0.792 0.892 0.821 0.829
Total Current Liabilities 65.463 69.015 85.416 67.15 73.204
Accounts Payable 14.466 13.478 14.673 10.58 14.667
Payable/Accrued 13.023 11.012 10.287 9.137 8.08
Accrued Expenses 28.972 37.045 40.55 33.326 34.603
Notes Payable/Short Term Debt 1.215 1.563 10.403 7.429 8.087
Current Port. of LT Debt/Capital Leases 0.062 0.085 3.305 0.09 0.925
Other Current Liabilities, Total 7.725 5.832 6.198 6.588 6.842
Total Liabilities 100.721 97.106 106.304 95.619 96.094
Total Long Term Debt 14.842 14.713 11.386 14.533 13.56
Long Term Debt 14.842 14.713 11.371 14.494 13.498
Capital Lease Obligations 0 0.015 0.039 0.062
Other Liabilities, Total 20.416 13.378 9.502 13.936 9.33
Total Equity 32.167 39.357 40.912 45.817 53.906
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.001 0.001 0.00038 0.00034 0.006
Additional Paid-In Capital 344.415 343.485 342.584 340.289 345.253
Retained Earnings (Accumulated Deficit) -312.249 -304.129 -301.672 -294.472 -291.353
Total Liabilities & Shareholders’ Equity 132.888 136.463 147.216 141.436 150
Total Common Shares Outstanding 5.53024 5.51717 3.77951 3.38315 3.12147
Total Preferred Shares Outstanding
Other Equity, Total -0.00038 -0.00034
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -110.173 -58.289 -13.6207 -27.1319 -10.1879
Cash From Operating Activities -28.823 -25.964 -28.3739 -13.8314 -15.9403
Cash From Operating Activities 10.251 9.201 6.24583 2.72707 2.59127
Deferred Taxes
Non-Cash Items 81.962 21.443 -8.38913 10.7837 -7.62492
Changes in Working Capital -10.863 1.681 -12.6099 -0.2102 -0.71881
Cash From Investing Activities -3.248 -2.782 -5.65577 -1.06199 -0.48429
Capital Expenditures -2.341 0 -0.05985 -0.07471
Other Investing Cash Flow Items, Total -3.248 -0.441 -5.65577 -1.00214 -0.40959
Cash From Financing Activities 1.53 30.314 71.0687 19.0751 22.6596
Financing Cash Flow Items -4.942 -10.996 -5.40415 -1.47996 -2.75752
Issuance (Retirement) of Stock, Net 11.694 45.051 92.7217 15.555 25.4171
Issuance (Retirement) of Debt, Net -5.222 -3.741 -16.2488 5
Net Change in Cash -30.541 1.568 37.0391 4.1817 6.23499
Cash Interest Paid 3.148 1.249 1.04028
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -14.594 -7.394 -2.881 -110.173 -92.472
Cash From Operating Activities -14.494 -11.588 -9.148 -28.823 -21.728
Cash From Operating Activities 6.699 4.505 2.328 10.251 8.005
Non-Cash Items 1.658 3.846 1.488 81.962 67.39
Cash Interest Paid 2.861 2.021 0.565 3.148 3.08
Changes in Working Capital -8.257 -12.545 -10.083 -10.863 -4.651
Cash From Investing Activities 0.038 0.037 0.042 -3.248 -3.207
Other Investing Cash Flow Items, Total 0.038 0.037 0.042 -3.248 -3.207
Cash From Financing Activities 14.275 11.692 13.557 1.53 2.647
Financing Cash Flow Items -5.254 -3.497 -1.107 -4.942 -4.429
Issuance (Retirement) of Stock, Net 13.012 11.573 10.416 11.694 12.7
Issuance (Retirement) of Debt, Net 6.517 3.616 4.248 -5.222 -5.624
Net Change in Cash -0.181 0.141 4.451 -30.541 -22.288
Capital Expenditures

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aytu BioScience, Inc. Company profile

About Aytu Biopharma Inc

Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Financial summary

BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.

Equity composition

Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.

Industry: Pharmaceuticals (NEC)

7900 E. Union Avenue
Suite 920
DENVER
COLORADO 80237
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.50 Price
+0.980% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,753.10 Price
-1.600% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,092.61 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

63,759.60 Price
-0.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading